Zimmer Biomet disclosed an enterprise resource platform transition issue at a competitor conference that is expected to be a 1% headwind to full year 2024 sales, or $75M in incremental pressure to rest-of-2024 top-line, Stifel analyst Rick Wise tells investors. The firm says Zimmer Biomet’s outlook will be negatively-impacted from the very recent, ongoing, and real ERP transition challenge and believes that in the very near-term, this headwind will likely pressure consensus rest-of-2024 sales, margin, and EPS estimates.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Zimmer Biomet sees ERP implementation impacting FY24 sales by about 1%
- Unusually active option classes on open September 5th
- Evercore estimates 15c EPS impact from Zimmer Biomet sales warning
- Zimmer Biomet Announces Quarterly Dividend for Third Quarter of 2024
- Zimmer Biomet price target lowered to $120 from $130 at Canaccord